XNAS
ATNF
Market cap508mUSD
Oct 20, Last price
3.25USD
1D
-7.26%
1Q
-45.84%
IPO
-99.99%
Name
180 Life Sciences Corp
Chart & performance
P/E
—
P/S
75.97
EPS
—
Vol. 1Y
120.07%
Shs. 5Y
343.15%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
7m
Net income
-450.52b
L+7,303,857.07%
CFO
-25m
L+1,608.33%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
1180 Life Sciences Corp. is a biotechnology firm currently in the clinical trial phase, dedicated to creating treatments for pressing medical challenges including chronic pain, inflammation, fibrosis, and other related inflammatory conditions. The company's therapeutic pipeline is supported by three primary development platforms: An anti-tumor necrosis factor (anti-TNF) and fibrosis platform is progressing through Phase IIb clinical trials, specifically targeting fibrosis and anti-TNF pathways. A Synthetic Cannabidiol (CBD) Analogs platform, featuring laboratory-created derivatives of CBD, is currently in preclinical development. An a7nAChR platform, which functions as an immune suppressive agent by focusing on the alpha 7 nicotinic acetylcholine receptor, is also undergoing preclinical evaluation. Established in 2016, 1180 Life Sciences Corp. is based in Palo Alto, California.
Key people
John Saunders
Chief Financial Officer, (Principal Accounting/Financial) and Secretary · since 2025
McAndrew Rudisill
Executive Chairman of the Board · since 2025
Director · since 2025
Angela Dalton
Independent Director · since 2025
Michael Edwards
Independent Director · since 2025
Crystal Heter
Independent Director · since 2025
Stephen Shoemaker
Independent Director · since 2024
Ryan Smith
Lead Independent Director · since 2025
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||